Mr Dennis R Oleary, CRNA | |
433 North Camden Dr Suite 1170, Office Surgical Suite Of Peter Giawbazzi Md, Bevererly Hills, CA 90210 | |
(818) 727-5908 | |
Not Available |
Full Name | Mr Dennis R Oleary |
---|---|
Gender | Male |
Speciality | Nurse Anesthetist, Certified Registered |
Location | 433 North Camden Dr Suite 1170, Bevererly Hills, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376636183 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | 602 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Dennis R Oleary, CRNA Po Box 7202 Ranch Station, Northridge, CA 91327-7202 Ph: (818) 727-5908 | Mr Dennis R Oleary, CRNA 433 North Camden Dr Suite 1170, Office Surgical Suite Of Peter Giawbazzi Md, Bevererly Hills, CA 90210 Ph: (818) 727-5908 |
News Archive
According to the the Royal College of Physicians (RCP), heavily-addicted smokers in Britain who find it impossible to quit are being let down.
OncoSec Medical Incorporated, which is developing its advanced-stage OMS ElectroOncology therapies for the treatment of solid tumor cancers, announced today the submission of its Device Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its patented OncoSec Medical System (OMS) which consists of a generator and hand-held applicator.
In 2017, Stanford University researchers presented a new device that mimics the brain's efficient and low-energy neural learning process.
Arizona Governor Jan Brewer on Tuesday signed into a law a bill allowing state health authorities to conduct surprise inspections of abortion clinics without first obtaining a warrant, handing another victory to abortion foes.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC).
› Verified 6 days ago